Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making

[61] Kantarjian H(2012)Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors J Clin Oncol Off J Am Soc Clin Oncol 30 232-1360

[62] O'Brien SG(2014)Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Blood 123 494-1688

[63] Druker BJ(2014)Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib Blood 123 1353-632

[64] Gorre ME(2013)Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months Haematologica 98 1686-518

[65] Mohammed M(2014)BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase Am J Hematol 89 626-1992

[66] Ellwood K(2014)Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline Blood 124 511-674

[67] Hsu N(2014)Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib Leukemia 28 1988-1035

[68] Paquette R(2017)Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? Expert Rev Hematol 10 659-305

[69] Rao PN(2010)Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 1029-522

[70] Sawyers CL(2017)Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia J Clin Oncol Off J Am Soc Clin Oncol 35 298-854

[61] Kantarjian H(2012)Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors J Clin Oncol Off J Am Soc Clin Oncol 30 232-1360

[62] O'Brien SG(2014)Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Blood 123 494-1688

[63] Druker BJ(2014)Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib Blood 123 1353-632

[64] Gorre ME(2013)Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months Haematologica 98 1686-518

[65] Mohammed M(2014)BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase Am J Hematol 89 626-1992

[66] Ellwood K(2014)Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline Blood 124 511-674

[67] Hsu N(2014)Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib Leukemia 28 1988-1035

[68] Paquette R(2017)Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? Expert Rev Hematol 10 659-305

[69] Rao PN(2010)Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 1029-522

[70] Sawyers CL(2017)Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia J Clin Oncol Off J Am Soc Clin Oncol 35 298-854